Lurbinectedin is a drug that is being developed for the treatment of different types of cancer. According to the sources provided, the drug has already received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) in patients who have received prior treatment [2]. The approval was granted based on the results of a clinical trial that showed that lurbinectedin was effective in shrinking tumors in SCLC patients [2].

However, the drug is still in the clinical trial phase for other types of cancer, such as ovarian and breast cancer [1]. A recent study published in the Journal of Clinical Oncology evaluated the efficacy and safety of lurbinectedin in patients with relapsed ovarian cancer [3]. The results of the study showed that lurbinectedin had a modest antitumor activity and manageable toxicity profile in patients with relapsed ovarian cancer [3].

In summary, lurbinectedin has already been approved by the FDA for the treatment of metastatic SCLC in patients who have received prior treatment [2]. However, the drug is still in the clinical trial phase for other types of cancer, such as ovarian and breast cancer [1]. Further studies are needed to evaluate the efficacy and safety of lurbinectedin in these types of cancer [3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532454/